Tandem Diabetes settles Roche patent disputes for $36 million paid over five years
On May 21, 2025, Tandem Diabetes and Roche entities agreed to settle all patent disputes over the t:slim X2 pump, terminating pending actions before Unified Patent Court divisions in France and Germany. The Tandem entities will pay $36 million over five years, starting with an $8 million initial payment, and the parties granted each other 10-year licenses to insulin delivery patents. The same day, shareholders elected all eight directors, approved executive pay on an advisory basis, and ratified Ernst & Young as auditor.
Key points
- Settlement resolves disputes over the t:slim X2 pump and two Roche-related EP patents, ending pending actions in France and Germany.
- Tandem entities will pay $36 million over five years: an $8 million initial payment, then four equal annual installments.
- Cross-licenses of insulin delivery system patents run for 10 years from the May 21, 2025 effective date.
- At the May 21, 2025 annual meeting, executive pay was approved with 54,337,934 for and 1,598,126 against, and shareholders chose an annual say-on-pay vote.
The filing
Written by AI on Nov 8, 2026, 6:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 23, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.